<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04170413</url>
  </required_header>
  <id_info>
    <org_study_id>14717</org_study_id>
    <nct_id>NCT04170413</nct_id>
  </id_info>
  <brief_title>Feasibility of Using Contrast Enhanced Voiding Urosonography (CeVUS) During Urodynamic Studies</brief_title>
  <official_title>Feasibility of Using CeVUS During Urodynamic Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will assess the feasibility of replacing fluoroscopy/iodinated contrast&#xD;
      with ultrasound/sulfur hexafluoride lipid-type A microspheres during routine urodynamic&#xD;
      studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Urodynamic studies routinely involve instillation of iohexol (OmnipaqueTM), a low osmolality&#xD;
      contrast agent, into the bladder followed by fluoroscopic imaging to assess for reflux or&#xD;
      variant anatomy of the genitourinary system. Recently, sulfur hexafluoride lipid-type A&#xD;
      microspheres (LumasonTM), an ultrasound contrast agent, has been approved in the United&#xD;
      States for intravesicular administration in the pediatric population. Contrast enhanced&#xD;
      voiding urosonography (CEvUS) is being increasingly utilized in the place of voiding&#xD;
      cystourethrograms, with the major advantages being decreased (zero) radiation for the&#xD;
      patient, as well as decreased cost. Given the similarity in procedure between urodynamic&#xD;
      studies (UDS) and voiding cystourethrograms, the investigators hypothesize that a urodynamic&#xD;
      study may be performed with contrast enhanced ultrasound instead of fluoroscopy. The&#xD;
      investigators plan to conduct a small feasibility study by recruiting a group of 30 patients&#xD;
      under the age of 18, who are willing to undergo their normally scheduled UDS in addition to&#xD;
      CEvUS. The UDS typically consists of two cycles of bladder filling and voiding; the&#xD;
      investigators intend to replace the use of fluoroscopy and iohexol with ultrasound and sulfur&#xD;
      hexafluoride lipid-type A microspheres. This will decrease the time commitment and eliminate&#xD;
      radiation exposure for the patient. There will not be a formal analysis of data as the&#xD;
      investigators are planning to test the feasibility of the procedure rather than gather any&#xD;
      quantitative data. The goal of the study is to eventually implement CEvUS instead of&#xD;
      fluoroscopy in all urodynamic and voiding studies if it is found to be a reasonable&#xD;
      alternative. This will decrease pediatric radiation exposure, which will be especially&#xD;
      important in the patients undergoing several studies each year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Actual">November 2, 2020</completion_date>
  <primary_completion_date type="Actual">November 2, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with successful completion of urodynamics</measure>
    <time_frame>After enrollment of 30 patients, estimated 1 year</time_frame>
    <description>All usual information gathered during urodynamics was able to be obtained</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">25</enrollment>
  <condition>Neurogenic Bladder</condition>
  <arm_group>
    <arm_group_label>CeVUS Urodynamic</arm_group_label>
    <description>patients undergoing urodynamic study with CeVUS</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CeVUS</intervention_name>
    <description>Contrast enhanced voiding urosonography</description>
    <arm_group_label>CeVUS Urodynamic</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric patients presenting to UVA Pediatric Urology for follow up or repeat urodynamics&#xD;
        study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 0-18&#xD;
&#xD;
          -  Must have had prior urodynamic study at University of Virginia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Fetuses&#xD;
&#xD;
          -  Neonates&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Subjects with preexisting cardiac conditions (such as heart failure and ventricular&#xD;
             arrhythmias)&#xD;
&#xD;
          -  Subjects with a known hypersensitivity to Lumason&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reza Daugherty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908-0170</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 14, 2019</study_first_submitted>
  <study_first_submitted_qc>November 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2019</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Reza Daugherty, MD</investigator_full_name>
    <investigator_title>Associate Professor of Radiology and Pediatrics</investigator_title>
  </responsible_party>
  <keyword>contrast ultrasound</keyword>
  <keyword>urodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Neurogenic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

